Stay updated on Pyrotinib vs Docetaxel in HER2 NSCLC Clinical Trial
Sign up to get notified when there's something new on the Pyrotinib vs Docetaxel in HER2 NSCLC Clinical Trial page.

Latest updates to the Pyrotinib vs Docetaxel in HER2 NSCLC Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedThe Study Record History now shows a new revision v3.6.5, superseding the previous v3.6.4. This indicates that the study record has been updated.SummaryDifference0.1%

- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedA new revision entry v3.6.4 has been added to the study record history, indicating an update to the record; the prior revision v3.6.3 is removed from the visible history.SummaryDifference0.1%

- Check44 days agoChange DetectedThe history gains a new revision entry for v3.6.3 and removes the prior v3.6.2, signaling that the record was updated to a newer version.SummaryDifference0.1%

- Check50 days agoChange DetectedA new revision label 'Revision: v3.6.2' is added to the record history and the older 'Revision: v3.6.0' tag is removed. This indicates a small update to the page's revision metadata without altering the underlying study data.SummaryDifference0.1%

- Check65 days agoChange DetectedRecruitment status now shows no longer looking for participants, indicating the study is not enrolling. The version history also shows a new revision tag v3.6.0 and the removal of v3.5.5.SummaryDifference0.4%

- Check72 days agoChange DetectedA new revision entry labeled v3.5.5 was added to the record history. The previous revision v3.5.4 was removed.SummaryDifference0.1%

Stay in the know with updates to Pyrotinib vs Docetaxel in HER2 NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pyrotinib vs Docetaxel in HER2 NSCLC Clinical Trial page.